The light-activated drug ASP-1929 is showing promise as a potential new treatment for people with recurrent head and neck squamous cell carcinomas. A new study of this first-in-class, precision targeted therapy is opening soon at Providence Cancer Institute.
Early trials demonstrate improvements in response rates, progression-free survival and overall survival compared with existing treatments. The drug received Fast Track designation from the FDA last year.
